Showing 2961-2970 of 6035 results for "".
- Quantel Medical Launches Mosar High-Definition Imaging System for for Easyrethttps://modernod.com/news/quantel-medical-lauches-mosar-high-definition-imaging-system-for-for-easyret/2478247/Quantel Medical announced the launch of Mosar, a high-definition imaging system, on its yellow laser Easyret. Mosar features an HD camera, a screen and computer, and enhances the retinal laser treatment procedu
- Nearly One Quarter of Chinese Children Hospitalized With COVID-19 Developed Eye Symptomshttps://modernod.com/news/nearly-one-quarter-of-chinese-children-hospitalized-with-covid-19-developed-eye-symptoms/2478244/Among Chinese children hospitalized for COVID-19, nearly a quarter developed ocular symptoms, a new study finds, Reuters reported. Most children developed eye symptoms later in the disease, but in nine, ocular manifestations were the first
- Nicox Completes Enrollment of the Adaptive Design Cohort of NCX 470 Mont Blanc Phase 3 Glaucoma Trialhttps://modernod.com/news/nicox-completes-enrollment-of-the-adaptive-design-cohort-of-ncx-470-mont-blanc-phase-3-glaucoma-trial/2478234/Nicox SA announced that it completed enrollment of the adaptive design patient cohort in its multicenter Mont Blanc phase 3 trial, evaluating NCX 470 ophthalmic solution vs. latanoprost ophthalmic solution 0.005% for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.
- Injectsense Receives Breakthrough Device Program Designation From FDA for IOP Monitoring Systemhttps://modernod.com/news/injectsense-receives-breakthrough-device-program-designation-from-fda-for-iop-monitoring-system/2478233/Injectsense announced it has received a breakthrough device program (BDP) designation from the FDA for its chronic continuous IOP monitoring system for glaucoma patients. The company’s IOP Connect system is based on a long-term implantable sensor, smaller than a grain of rice, that is delivered t
- ReVision Therapeutics Announces License With Cornell to Develop Treatment for Stargardt Diseasehttps://modernod.com/news/revision-therapeutics-announces-license-with-cornell-to-develop-treatment-for-stargardt-disease/2478230/ReVision Therapeutics announced that it has signed an exclusive license agreement with Cornell University for the development and commercialization of Cornell’s proprietary technology for the treatment of Stargardt disease, a genetic d
- Genentech Initiates Phase 3 Trial for Port Delivery System with Ranibizumab in Diabetic Retinopathyhttps://modernod.com/news/late-stage-trial-starts-for-port-delivery-system-with-ranibizumab-in-diabetic-retinopathy/2478224/Genentech has initiated a new phase 3 clinical trial investigating Port Delivery System with ranibizumab (PDS) for people with diabetic retinopathy (DR). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customized formulation of r
- Seva Foundation Partners With IrisVision to Democratize Vision Care Through Innovationhttps://modernod.com/news/seva-foundation-partners-with-irisvision-to-democratize-vision-care-through-innovation/2478208/IrisVision announced it has partnered with the Seva Foundation to develop new technology that aims to democratize vision healthcare around the world. In the first phase of this unique public-private partnership, Seva, a global non-profit organization that provides eye
- ForwardVue Pharma Secures Funding to Advance Preclinical Development Programshttps://modernod.com/news/forwardvue-pharma-secures-funding-to-advance-preclinical-development-programs/2478206/ForwardVue Pharma has secured initial seed round funding in order to advance preclinical development of potent long acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration. Based on this progress, ForwardVue has announced a ne
- Regenxbio Announces FDA Clearance of IND for Phase 2 Trial of RGX-314 for the Treatment of DR Using Suprachoroidal Deliveryhttps://modernod.com/news/regenxbio-announces-fda-clearance-of-ind-for-phase-2-trial-of-rgx-314-for-the-treatment-of-dr-using-suprachoroidal-delivery/2478202/Regenxbio announced the clearance of the investigational new drug (IND) application by the FDA to evaluate the suprachoroidal delivery of RGX-314 in patients with diabetic retinopathy (DR). The IND is active, and Regenxbio plans to begin dosing patients in a phase 2 trial, ALTITUDE, in the second
- Gyroscope Therapeutics Announces FDA Clearance of Orbit Subretinal Delivery Systemhttps://modernod.com/news/gyroscope-therapeutics-announces-fda-clearance-for-orbit-subretinal-delivery-system/2478198/Gyroscope Therapeutics announced that the FDA has granted 510(k) clearance for the Orbit Subretinal Delivery System (Orbit SDS). The Orbit SDS is indicated for microinjection into the subretinal space at the back of the eye. The microinjection procedure is designed to avoid damaging the structure